Engineered immune cells take on tough leukemia
NCT ID NCT07370064
First seen Jan 30, 2026 · Last updated May 12, 2026 · Updated 9 times
Summary
This early-phase trial tests a new type of CAR-T cell therapy for people with acute myeloid leukemia (AML) that has come back or not responded to standard treatments. The therapy uses a patient's own immune cells, modified to better find and attack leukemia cells. The study aims to see if this treatment can shrink or eliminate the cancer and will closely monitor safety. It is open to adults aged 18 and older who have tried at least one prior therapy.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AML (ACUTE MYELOID LEUKEMIA) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
The Affiliated Hospital oh Xuzhou Medical University
Xuzhou, Jiangsu, 221006, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.